Comparative analysis of safoof-e− muhazzil and orlistat on obesity and markers of obesity

Abstract

Introduction

Obesity is truly a pandemic and associated with increased risk of multiple non-communicable diseases. The available pharmacotherapy of obesity is associated with multiple limitations. We have studied the effect of sufoof e muhazzil and compared it with orlistat in non-diabetic patients with obesity.

Material and methods

It was an open-label, interventional prospective study including 200 patients with obesity. These patients, aged between 18 and 60 years, had a body mass index (BMI) of 25–40 kg/m². We divided them equally between the Sufoof e Muhazzil and Orlistat groups. The dose of sufoof e muhazzil was 6 gm/day, and orlistat was 120 mg twice daily for 2 months. We assessed the effect on weight, BMI, biochemical, and inflammatory markers at the onset and at the end of the study.

Result

The mean age, weight, BMI, and waist circumference were 37.85 years and 35.71 years, 80.7 kg and 74.9 kg, 32.7 kg/m² and 32.4 kg/m², and 113.0 cm and 112.5 cm, respectively, for the orlistat and sufoof groups. There was a significant reduction in weight, BMI, and abdominal circumference in both groups (p value < 0.001 for all). Biochemical and inflammatory parameters also improved significantly in both groups. Sufoof e muhazzil use was associated with greater reductions in weight (5.8 vs 4.4 kg), BMI (2.5 vs 1.9 kg/m²) than orlistat.

Conclusion

Both orlistat and sufoof e muhazzil are associated with significant weight reduction and improvement in biochemical and inflammatory parameters. Both the drugs demonstrated excellent safety and tolerability.